Published in Blood Weekly, June 6th, 2002
The granting of this regulatory approval enables the two companies to move forward with their plans to advance the clinical development and commercialization of ISA(TX)247.
"This approval is great news for Isotechnika and Roche and for transplantation patients around the globe" states Koziak. "This judgment validates the continuing need in the market place and the world transplant community...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.